Novel targeted therapeutics for metastatic castration-resistant prostate cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard of care for these patients and is associated with a modest prolongation of survival, there is an urgent need for novel treatment strategies for metastatic prostate cancer. In the last several years, great strides have been made in our understanding of the biological and molecular mechanisms driving prostate cancer growth and progression, and this has resulted in widespread clinical testing of numerous new targeted therapies. This review discusses some of the key therapeutic agents that have emerged for the treatment of metastatic castration-resistant prostate cancer in the last 5 years, with an emphasis on both molecular targets and clinical trial design. These agents include mammalian target of rapamycin (mTOR) pathway inhibitors, anti-angiogenic drugs, epidermal growth factor receptor (EGFR) inhibitors, insulin-like growth factor (IGF) pathway inhibitors, apoptosis-inducing drugs, endothelin receptor antagonists, receptor activator of nuclear factor κB (RANK) ligand inhibitors, vitamin D analogues, cytochrome P17 enzyme inhibitors, androgen receptor modulators, epigenetic therapies, vaccine therapies, and cytotoxic T lymphocyte-associated antigen (CTLA)-4 blocking agents.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCancer Letters
Volume291
Issue number1
DOIs
StatePublished - May 1 2010

Keywords

  • Clinical trials
  • Drug development
  • Immune therapies
  • Metastatic castration-resistant prostate cancer
  • Molecular targets
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Novel targeted therapeutics for metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this